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Abbreviations 18 
MGE (mobile genetic elements), GFP (green fluorescent protein), NO (nitric oxide), MIC (minimal 19 
inhibitory concentration), CLSI (Clinical and Laboratory Standard Institute), LB (Luria Bertani), CV 20 
(crystal violet), CLSM (Confocal Laser Scanning Microscopy), UV (Ultraviolet), HPLC (High 21 
pressure Liquid Chromatography), ANOVA (Analysis of Variance), DMSO (dimethyl sulfoxide). 22 
 23 
Abstract  24 
Pseudomonas aeruginosa is a microorganism that is well adapted to both clinical and industrial 25 
settings, where it can form adherent communities that are difficult to eradicate. New anti-26 
Pseudomonas compounds and strategies are necessary, as the current antimicrobial approaches for 27 
the inhibition of biofilm formation and, above all, the eradication of formed biofilms are ineffective. 28 
Compounds that belong to the furoxan-family, which are well-known NO donors, have recently 29 
been shown to display anti-Pseudomonas activity. The present study investigates three furoxan 30 
compounds that are substituted at the heteroring with electron-withdrawing groups (NO2, CN, 31 
CONH2) for their effects on P. aeruginosa PAO1 growth and biofilm formation/dispersal. Of the 32 
furoxans tested, only 3-nitro-4-phenylfuroxan (KN455) inhibited the growth of suspended P. 33 
aeruginosa PAO1 cultures. Furthermore, KN455 inhibited the formation of both younger and older 34 
biofilms with very high yields and thus proved itself to be toxic to planktonic subpopulations. It also 35 
displayed moderate eradicating power. The activity of KN455 does not appear to be related to its 36 
capacity to release small amounts of NO. Interestingly, the isomer 4-nitro-3-phenylfuroxan (KN454), 37 
included for comparison, displayed a comparable antibiofilm rate, but did not show the same 38 
antimicrobial activity against suspended cells and planktonic subpopulations. While hypotheses as to 39 
the mechanism of action have been formulated, further investigations are necessary to shed light onto 40 
the antimicrobial activity of this furoxan. 41 
 42 
  43 
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Introduction 44 
Pseudomonas aeruginosa is a microorganism that is optimally adapted to a variety of 45 
environmental conditions and is ubiquitously present in soil, water and sewage as well as in human, 46 
animal and plant hosts [1]. P. aeruginosa is also known to be a human opportunistic pathogen as it 47 
plays an important role in infections such as pneumonia in cystic fibrosis patients, chronic-wound 48 
infections and medical-device-related infections [2, 3]. 49 
Treatment of P. aeruginosa infections is often a challenge due to its resistance to antibiotics, 50 
which is acquired via a number of mechanisms. P. aeruginosa secretes enzymes, including β-51 
lactamases and aminoglycoside modifying enzymes, that inactivate antibiotic molecules. It can also 52 
reduce antimicrobial agent accumulation in the cell producing multidrug efflux pumps (i.e. MexAB-53 
OprM, MexEF-OprN, MexCD-OprJ, MexXY-OprM, etc.) [4]. Chromosomal mutations in DNA 54 
gyrase and topoisomerase IV genes lead to resistance towards quinolones [5]. The isolation of 55 
multidrug-resistant strains is increasing in clinical settings, where antibiotic selection is routinely 56 
practiced. Furthermore, the transfer of mobile genetic elements (MGE) contributes to the spread of 57 
resistance determinants among strains that belong to the same species and those of different species 58 
[6]. P. aeruginosa is also able to contaminate disinfectants such as chlorhexidine, benzalkonium and 59 
triclosan [7]. 60 
The treatment of P. aeruginosa infections becomes more difficult when bacteria are encased in 61 
their self-made matrix. This tolerance is caused by restricted compound penetration through the 62 
exopolysaccharide matrix and decreased metabolism, which is due to low nutrient and oxygen levels 63 
and accumulated waste [8]. The inhibition of biofilm formation and the eradication of mature biofilms 64 
are goals that are important for a wide range of antimicrobial applications  because microbial biofilms 65 
are not only a significant issue in clinical infections, but also in the biofouling of industry water 66 
systems. Anti-biofilm strategies either attempt to destroy the established community in its 67 
microenvironment or target a specific step within the biofilm cycle. Biofilm disruption and/or 68 
corrosion can be achieved by metal chelators, such as EGTA and EDTA [9], by surfactants, such as 69 
SDS [10], by D-amino acids [11], and, as found more recently, by photoantimicrobials [12,13]. 70 
 Nitric oxide (NO) has recently emerged as an endogenous regulator of biofilms [14]. Low 71 
levels of NO induce a transition from the biofilm mode of growth to the planktonic form [15]. A 72 
number of NO donors, products that can release NO under physiological conditions, have been found 73 
to suppress biofilm formation and elicit dispersal events in P. aeruginosa [15, 16, 17]. Furoxans 74 
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(1,2,5-oxadiazole N-oxides) are an interesting class of NO donors. A recent study has described the 75 
effects of three furoxan derivatives that are able to spontaneously release nitrogen oxide species 76 
(NOx), namely NO and nitrite (NO2
−), on P. aeruginosa PAO1 biofilm formation and dispersion [18]. 77 
The present work extends our research into the use of furoxan derivatives as potential PAO1 78 
antibiofilm tools, and focuses on the impairment of P. aeruginosa biofilms using furoxan derivatives, 79 
which release NO under the action of thiol cofactors. Phenylfuroxan derivatives with electron 80 
withdrawing substituents (NO2, CN, CONH2) at the 3 position of the heteroring (Figure 1) are 81 
investigated for their effect on P. aeruginosa biofilm formation in this work, as electron-withdrawing  82 
groups have been shown to facilitate the release of NO from furoxans [19, 20]. 3-Nitro-4-83 
phenylfuroxan (KN455), 3-cyano-4-phenylfuroxan (CF357) and 4-phenyl-3-furoxancarboxyamide 84 
(CF1656) have been selected for this study. The isomer 4-nitro-3-phenylfuroxan (KN454) is included 85 
for comparison, as is the related des-NO furazan, 3-nitro-4-phenylfurazan (CF389). 86 
Materials and methods  87 
Synthesis of the tested compounds 88 
Compounds KN455 [21]), CF357 [22], CF1656 [23], CF389 and KN454 [24] were synthetized 89 
as previously described. 90 
Bacteria strains and growth conditions 91 
Pseudomonas aeruginosa PAO1 was chosen as the model biofilm microorganism [25]. PAO1 92 
was transformed using the pVO(GFP) expression vector; it is a pJB3 KmD derivative, in which the 93 
Green Fluorescent Protein (GFP) coding sequence was cloned under an arabinose inducible promoter 94 
(pAra). Both strains were grown overnight in LB medium at 37°C under 200 rpm shaking. 95 
Antimicrobial assays 96 
A modified disk diffusion assay (Kirby-Bauer test) was set up to test the sensitivity that P. 97 
aeruginosa PAO1 shows towards furoxans [26]. Microorganisms grown in LB overnight at 37°C 98 
were diluted 100-fold in phosphate buffer (KH2PO4/K2HPO4 10 mM, pH 7.4) and a 100 l sample 99 
was plated onto LB Agar. Filter paper disks (bioMerieux) with 6 mm diameters were loaded with 100 
increasing volumes of furoxans/furazan (20, 15, 10 and 5 l) at a concentration of 50 mM, and placed 101 
on LB Agar. A disk loaded with 20 l DMSO was used as a control. The plates were incubated at 102 
37°C for 24 h and the antibacterial effect was evaluated by measuring the growth inhibition halo. 103 
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In order to evaluate the furoxans’ Minimal Inhibitory Concentration (MIC) toward P. aeruginosa 104 
PAO1, according to guidelines from CLSI (Clinical and Laboratory Standard Institute) [27], bacteria 105 
were grown overnight in LB at 37°C and diluted 100-fold to give a cellular concentration of 107 CFU 106 
ml-1. Two-fold dilutions of KN455, CF357, CF1656, KN454 and CF389 (from 2 to 0.001 mM), were 107 
added to bacterial samples. The dilution series were observed for microbial growth after 24 hours of 108 
incubation at 37°C and MIC values were evaluated. MBC (Minimal Bactericidal Concentrations) 109 
values were determined by re-culturing dilutions that inhibited PAO1 growth (i.e. those at or above 110 
the MIC). Broth dilutions were streaked onto LB agar and incubated for 24 to 48 hours. The MBC 111 
was the lowest broth dilution of furoxan/furazan that prevented P. aeruginosa PAO1 growth on the 112 
agar plate. All experiments were performed in triplicate, at least. 113 
Biofilm assays 114 
Overnight-PAO1 cultures were diluted 1:200 times in M9 medium that was supplemented with 115 
glucose 10 mM and 0.2% w/v casamino acid, used as carbon and nitrogen sources respectively, to 116 
obtain homogenous and repeatable biofilms [28, 29, 30]. One ml of the diluted culture was added to 117 
each well of a 24-well polystyrene plate. The furoxans were administered at three different 118 
concentrations (5, 50 and 500 M) and dimethylsulfoxide (DMSO) 0.5 % was used as a solvent 119 
control. L-cysteine 5 mM, NO scavenger 2-phenyl-4,4,5,5,-tetrame-thylimidazoline-3-oxide-1-oxyl 120 
(PTIO) 1 mM and sodium nitrite, at 0.01, 0.1 and 0.5 mM, were added when indicated. The cells were 121 
incubated at 37°C under 200 rpm shaking for 6 h to evaluate the inhibitory effect of furoxans. The 122 
biofilm dispersal effect of the furoxans was observed upon administering compounds for 1 h, after 5 123 
h of untreated biofilm growth [18]. 124 
Planktonic biomass was spectrophotometrically quantified for each well via a measurement of 125 
absorbance at 600 nm, while adherent biomass was quantified via crystal violet (CV) staining. Briefly, 126 
planktonic biomass was removed and collected, and wells were washed once with one ml phosphate 127 
buffer. One ml of 0.1% CV was added to each well for approximately 20 min to stain the biofilm, 128 
after which the CV was removed and each well washed twice with 1 ml phosphate buffer. The 129 
remaining CV, which indicated the amount of biofilm present, was dissolved in acetic acid 30 % for 130 
10 min. The amount of solubilized dye was spectroscopically measured at 595 nm.  131 
In order to evaluate the effect of the different treatments on the cellular viability of suspended 132 
and adherent populations, the planktonic phase was axenically collected and adherent cells were 133 
recovered by scraping and suspended in 1 ml of phosphate buffer. Viable counts - expressed as colony 134 
forming units per mL, CFU ml-1, in cell suspensions and as CFU per well in adherent biomass - were 135 
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estimated using a plate count technique; a volume (0.01 ml) of undiluted or serially diluted samples 136 
was plated onto LB Agar plates and incubated for 24 h at 37°C. All experiments were independently 137 
repeated at least three times. 138 
Confocal analyses  139 
Overnight PAO1- GFP tagged cultures were diluted 1:200 times in M9 medium that was 140 
supplemented with glucose 10 mM and 0.2% w/v casamino acid. Five ml of the diluted culture was 141 
added to a glass coverslip and placed into a well of a 6-well polystyrene plate. Volumes of the 142 
furoxans, 500 M, and DMSO 0.5 % were added to the bacteria and subsequently incubated at 37°C.  143 
After either 24 h or 48 h of incubation, cells were induced with arabinose 1 mM to express green 144 
fluorescent protein. The coverslip was placed on a microscope glass slide for the acquisition of the 145 
adherent biofilm image. In order to observe the suspended bacteria, cells were placed between the 146 
glass and coverslip after 24 hours of treatment with furoxan/furazan 125 M and DMSO 0.5 % as 147 
control. All microscopy observation and image acquisition was performed on a Leica TCS SP5 148 
confocal laser scanning microscope (CLSM) (Leica Microsystems, Wetzlar, Germany) equipped with 149 
a detector and filter set for GFP monitoring. Images were obtained using a 63/1.3 objective lens. 150 
Simulated 3D images were generated using the free, open-source software ImageJ (National Institute 151 
of Healt, USA). 152 
NO and NO2- detection 153 
Nitrite measurements by Griess reaction 154 
The total release of NOx was evaluated as nitrite (NO2
-) using the Griess reaction. Compounds were 155 
incubated at 37°C in 50 mM phosphate buffer, pH 7.4 at 0.1 mM concentration (thus final 1% DMSO) 156 
either in the absence or in the presence of L-cys at 0.1, 0.5 or 1 mM (1, 5 and 10 times mol/mol 157 
excess). The presence of nitrite in the reaction mixture was determined using the Griess assay at 158 
regular time intervals; 1 ml of the reaction mixture was treated with 250 l of the Griess reagent (4% 159 
w/v sulphanilamide, 0.2 % w/v N-naphthylethylenediamine dihydrochloride, 1.47 M phosphoric 160 
acid). Absorbance was measured at 540 nm on a UV spectrophotometer after 10 min at room 161 
temperature (UV-2501PC, Shimadzu). A calibration curve was obtained using standard solutions of 162 
sodium nitrite in a concentration range of 1-80 µM (r2 > 0.99). The yield in nitrite was expressed as 163 
NO2
- percentage (mol/mol, relative to the initial compound concentration)  SEM. 164 
NO measurements using the DAN (2,3-diaminonaphthalene) method  165 
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NO release from furoxan compounds was quantified using a 2,3-diaminonaphthalene (DAN)-based 166 
chemical assay. This assay is based on the immediate reaction of NO with oxygen (O2) to form 167 
dinitrogen trioxide (N2O3), which then reacts with non-fluorescent DAN to form the highly 168 
fluorescent 2,3-naphthotriazole (NAT), which can be quantified by RP-HPLC. Compounds were 169 
incubated at 37°C in 50 mM phosphate buffer, pH 7.4 at 0.1 mM concentration (then final 1% DMSO) 170 
with 0.2 mM (2 times mol/mol excess) DAN, either in the absence or in the presence of L-cys at 0.5 171 
mM. The presence of NAT in the reaction mixture was evaluated using HPLC analysis at fixed time 172 
points, according to a previously published protocol [31]. HPLC analyses were performed using a HP 173 
1200 chromatograph system (Agilent Technologies, Palo Alto, CA, USA) that was equipped with a 174 
quaternary pump (model G1311A), a membrane degasser (G1322A), a UV detector, MWD (model 175 
G1365D), and a fluorescence detector (model G1321A), all integrated into the system. Data analyses 176 
were performed on a HP ChemStation system (Agilent Technologies). The sample was eluted on a 177 
Zorbax Eclipse XDB-C18 column (150 × 4.6 mm, 5 μm; Agilent); the injection volume was 20 μl. 178 
The mobile phase consisted of 65% 15 mM potassium phosphate buffer (pH 8.0) and 35% acetonitrile 179 
at a flow rate of 1.00 ml min-1. The fluorescence signals were obtained at excitation and emission 180 
wavelengths of 355 and 460 nm, respectively (gain factor = 10). Data manipulation was performed 181 
using an Agilent ChemStation. The values obtained from integrating the NAT peak were interpolated 182 
into a calibration line that was prepared using NaNO2 (in acidic conditions) as a standard. Briefly, 183 
sodium nitrite standard solutions were acidified with HCl (pH 2) in the presence of an excess of DAN 184 
(0.2 mM). The reaction mixture was diluted in a phosphate buffer after 10 min (at pH = 7.4 and NO 185 
final concentration 1 to 80 µM), and analysed by HPLC. 186 
Statistical analyses 187 
Experiments were repeated at least three times on separate dates. Mean and SD calculations 188 
were performed using Microsoft Excel 2010. Data were analysed by means of one-way ANOVA 189 
(Origin_ 7.0 SR0; Origin lab) and the statistical significance of all treatments was estimated (P < 0.05 190 
and P < 0.01). 191 
Results 192 
Effect of furoxans on P. aeruginosa PAO1 growth 193 
The furoxans KN455, CF357 and CF1656, which bear different substituents on the 3 position 194 
of the furoxan heteroring (Figure 1), were investigated for their effect on P. aeruginosa PAO1 growth, 195 
both in solid and liquid media. As a first step, a Kirby-Bauer test was performed to assay the activity 196 
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of the three compounds. The DMSO used to dissolve the furoxans did not influence bacterial growth. 197 
Of the three compounds, only KN455 provided a reproducible inhibition growth halo (12.3 ± 0.57 198 
mm). In order to investigate the possible involvement of nitric oxide (NO) in the observed inhibitory 199 
activity, the corresponding furazan CF389, which is known not to release NO, was included in the 200 
analysis and no inhibition halo was observed (Figure 2). Furthermore, the corresponding 4-nitro 201 
isomer (KN454) was assayed to evaluate whether the nitro position on the heteroring influenced 202 
antimicrobial activity. In fact, KN454 failed to show any antimicrobial activity (Figure 2) and 3-nitro-203 
4-phenylfuroxan was the only active compound. Furthermore, its activity was dose-dependent (data 204 
not shown).  205 
The MIC value of KN455 was 125 M, and the MBC value 250 M, meaning that its Killing 206 
Quotient, calculated as MBC/MIC ratio, was lower than 4. This would indicate that the effect of 207 
KN455 is bactericidal. The MIC value of its isomer KN454 was 1 mM, whereas the MIC values of 208 
furoxans CF357 and CF1656, and furazan CF389 were all higher than 2 mM. 209 
Confocal analyses were performed to evaluate the effect of KN455 on suspended PAO1 cells. 210 
The PAO1 strain was transformed with the Green Fluorescent Protein-gene-carrying plasmid, pVO, 211 
under the control of the araBAD promoter. Upon induction with arabinose, the cultures produced 212 
enough GFP to give a fluorescent signal, while cells that were not induced with arabinose were not 213 
fluorescent (data not shown). Upon 24 hours of treatment with KN455 125 M (MIC), few survivors  214 
were detected and most showed morphological changes compared to untreated (not shown) and 215 
DMSO 0.5 % treated cells (3A). As seen in Figure 3B, the surviving bacteria are longer than the 216 
untreated cells. In fact, the binary division process seems to be impaired, septation appears to be 217 
incomplete and giant cells are present in the treated group. Moreover, some of the filamentous rods 218 
show bright fluorescence while others show less pronounced GFP fluorescence. CF389 (Figure 3C) 219 
and KN454 125 M (data not shown) did not impaired the cellular viability as KN455, however few 220 
long cells were detectable. The administration of CF1556 (Figure 3D) and CF357 (data not shown) 221 
did not cause any change in cellular density, GFP expression and bacterial morphology.  222 
Effect of furoxans on the inhibition of P. aeruginosa biofilm formation 223 
As it is known that furoxans release NO, the effect of increasing furoxan concentration (5, 50 224 
and 500 M) on PAO1 biofilm formation was investigated. Compounds were added to minimal 225 
medium together with PAO1 and the adherent biomass was examined using crystal violet staining 226 
after 6 hours of incubation. Compounds were dissolved in DMSO 0.5 %, without significantly 227 
changing the amount of adherent biomass (p = 0.61) compared to untreated controls (data not shown). 228 
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The nitro substituted furoxan, KN455, provided the most significant and dose-dependent biofilm 229 
inhibition of the three different furoxans tested, giving significant inhibition rates at the highest 230 
concentrations of 50 and 500 M, respectively (Figure 4A). The CN substituted furoxan, CF357, 231 
inhibited biofilm formation in a significant manner (p = 0.014) at 500 M (Figure 4B), while the 232 
CONH2 substituted analogue, CF1656, did not show any anti-biofilm effect at any tested 233 
concentration (Figure 4C). As the nitro derivative showed the highest inhibitory activity, its 4-nitro 234 
isomer KN454 and the corresponding des-NO furazan analogue, CF389, were also tested for their 235 
ability to inhibit biofilm formation. The rates of inhibition caused by KN454 and CF389 at the highest 236 
tested concentrations were  statistically significant as shown in figures 4D and 4E, respectively (data 237 
not shown). 238 
The viability of sessile biofilm cells was checked and KN455, alone among the tested furoxans, 239 
displayed a toxic effect against this sub-population (Figure 5A). A ~3-log unit decrease, compared to 240 
untreated cells, was observed. The corresponding 4-nitro isomer, KN454, and furazan, CF389, caused 241 
2-log unit decreases when administered at 500 M. 242 
The planktonic counterparts of each biofilm were also evaluated as they play an important role 243 
in bacterial dissemination and equilibrium maintenance in the biofilm community. DMSO 0.5 % did 244 
not influence the cellular viability of planktonic biomass, compared to untreated cells (data not 245 
shown), while KN455 provided a much more significant decrease in viable cells (p = 3.2 x 10-7) than 246 
the untreated samples (Figure 5B). Furoxans, CF357 and CF1656, did not alter the viability rate of 247 
cells (Figure 5B). Furazan CF389 and furoxan KN454 only caused a 1-log unit decrease, compared 248 
to untreated control biofilms. 249 
 Confocal analyses of 24- and 48-hour-old biofilms showed that the inhibitory effect of KN455 250 
500 M was also reliable when used in prolonged treatment (Figure 6). The GFP signal of a furoxan-251 
incubated biofilm was lower than those of untreated and DMSO 0.5 % v/v treated biofilms. KN455's 252 
inhibitory effect was also evident against a 48-hour-old biofilm, which was noticeably thicker than 253 
the 24-hour-old biofilm (Figure 6). The corresponding furazan CF389 was not as effective as KN455, 254 
especially against 48 hour old biofilm (figure 6). 255 
Effect of furoxans on biofilm eradication 256 
While the inhibition of biofilm formation is an important goal, biofilm eradication is much more 257 
difficult to achieve and antimicrobials usually fail. The compounds were administered at 500 M for 258 
1h to cells grown for 5h to assay biofilm eradication power. The solvent was not toxic to cells (data 259 
not shown). KN455 showed the most statistically significant (p = 9.65 x 10-4) eradication power, of 260 
the furoxans tested (Figure 7). The decreases in adherent biomass caused by isomer KN454 and des-261 
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NO furazan CF389 were not significant. The solvent was not toxic to cells in tests on planktonic 262 
counterparts and the biomass changes observed upon furoxan treatment were not significant (data not 263 
shown), compared to control samples DMSO treated biofilms. 264 
 265 
Insight into anti-Pseudomonas activity of KN455 266 
KN455 was the most effective anti-Pseudomonas agent of the furoxans tested as it inhibited 267 
both cellular growth and biofilm formation, and even showed moderate biofilm eradicating power. 268 
The kinetics of NOx release from KN455 were compared to those of the other furoxans, CF357 and 269 
CF1656, because it this thought that NO may play the role of anti-biofilm messenger. Furthermore, 270 
the isomer KN454 and corresponding furazan CF389, which were included in the antimicrobial and 271 
antibiofilm assays, are also included in Figure 8, as % mol/mol. The amounts of NO2
- detected for 3-272 
nitro-4-phenylfuroxan (KN455) were about 130 mol/mol after 1 hour. The amount of NO2
- produced 273 
by KN455 is the sum of the NO2
- formed by the nucleophilic substitution of the nitro group (see 274 
supporting information, S1, pathway a), and of the NO2
- produced by the aerobic oxidation of the NO 275 
released following the ring opening of the tetrahedral intermediate precursors (see supporting 276 
information, S1, pathways b, R=NO2, R = CyS). DAN (2,3–diaminonaphtalene) assays (Fang et al. 277 
2009), which allow NO centre dots to be specifically detected, were carried out to shed further light 278 
onto this process. NO2
- was the dominant species produced by KN455 after 1 h, whereas NO only 279 
corresponded to 5% of total NOx. The amount of NO2
- detected for the 4-nitro isomer KN454 was 280 
about 80 % mol/mol after 1 hour (Figure 8). For the desNO-nitrofurazan CF389, which cannot release 281 
NO from the heterocycle core, the reaction rate was slower and the amount of NO2
- detected was 25 282 
% mol/mol after 1 hour (Figure 8). 3-cyanofuroxan, CF357, and 3-carbamoylfuroxan, CF1656, 283 
produced nitrite in good and modest amounts, respectively. However, it is worth noting that these 284 
yields derived exclusively from the oxidation of NO (DAN test).  285 
The highest rate of NO release was displayed by CF357, which, however, showed low anti-286 
biofilm activity. Furoxans KN455 and CF1656, which release the same very low NO amount, showed 287 
different effects on microbial growth and biofilm formation. These data seem to rule out the possible 288 
involvement of NO in KN455 toxicity. 289 
In order to investigate this hypothesis, biofilm formation experiments were repeated in the 290 
presence of PTIO, a known NO radical scavenger, and no changes were observed (data not shown). 291 
The possible involvement of nitrite, the other species released in large amounts by KN455, was also 292 
evaluated. The biofilm inhibition effect induced by acidified sodium nitrite was checked and 293 
compared to that of equimolar increasing concentrations of KN455. Sodium nitrite was less active 294 
than KN455 at the tested concentrations (Figure 9). 295 
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Since previous studies have shown that thiol groups, such as those present in L-cysteine (L-296 
cys), can promote the liberation of NOx (NO and NO2
-) from furoxan compounds (Feelisch M. et al. 297 
1992), PAO1 was treated with increasing concentrations of KN455 in the presence of an excess of 298 
cysteine 5mM. L-Cysteine decreased the anti-biofilm activity of 50 M and 500 M KN455 (Figure 299 
10). Furthermore, L-cysteine abolished the anti-biofilm activity of KN455-related compounds, 300 
KN454 and CF389 (data not shown). 301 
The reaction between L-cysteine and KN455 was monitored by HPLC in order to more deeply 302 
probe the role played by thiol groups. HPLC/mass data (Figure S2) indicate that, after 20 min, the 303 
compound was almost quantitatively transformed into 3-cysteinyl-4-phenylfuroxan (282 M+1, 120 304 
M-cysteinyl), which is the product of the nucleophilic substitution of the 3-nitro group with cysteine 305 
(see supporting information S1, pathway a). Over time, this latter compound was largely transformed 306 
into unidentified products and NO2
- (see supporting information S1, pathway b). The 4-nitro isomer, 307 
KN454, also reacted with L-cysteine giving rise to the corresponding cysteinyl derivatives (see 308 
supporting information S3). Des-NO furazan CF389, which cannot release NO from its heterocycle 309 
core, behaved similarly and afforded the cysteinyl substituted product. 3-Cyanofuroxan, CF357, and 310 
3-carbamoylfuroxan, CF1656, produced nitrite and unidentified products (see supporting information 311 
S4).  312 
Discussion 313 
Previous studies have shown that thiol groups, such as those present in L-cysteine (L-cys), can 314 
promote the liberation of NOx from furoxan compounds and increase their activity [18]. In this study, 315 
three phenylfuroxan derivatives that can release varying amounts of NOx were assayed for their 316 
antimicrobial activity against P. aeruginosa PAO1, and it would appear that the substituent influences 317 
furoxan antimicrobial activity; the NO2-substituted analogue, KN455, inhibited the growth of PAO1, 318 
whereas CN- and CONH2-substituted furoxans did not show any antimicrobial activity in the solid 319 
media. Furthermore, KN455 activity was bactericidal. Interestingly, the position of the nitro group 320 
on the furoxan skeleton significantly influences antimicrobial activity against P. aeruginosa PAO1; 321 
KN454 did not show any inhibition halo in the solid media and its MIC value was four-times higher 322 
than that of KN455.  323 
Furthermore, the chosen furoxans showed different NOx release rates. As NO is emerging as 324 
an anti-biofilm messenger [32], the biofilm formation inhibition activity of the furoxans was 325 
investigated and correlated with NOx release. KN455, which is characterized by very low NO release, 326 
proved itself to be the most active compound in inhibiting biofilm formation, whereas CF357 and 327 
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CF1656, which can release good and very low amounts of NO, respectively, showed weak or null 328 
activity even at the highest concentrations tested. CF389, which is known not to release NO, and 329 
KN454, which releases nitrite, showed inhibitory activity. It would thus appear that nitric oxide does 330 
not play a role in furoxan biofilm inhibition. Indeed, KN455 was very toxic and no viable cells were 331 
recovered from the planktonic subpopulation of the six-hour-old biofilms. By contrast, the 4-nitro 332 
isomer KN454 was not toxic to the planktonic subpopulation, and only caused a slight decrease in 333 
cellular viability. The two furoxans showed different selectivities against biofilm cellular 334 
subpopulations; KN455 inhibited the growth of both planktonic and adherent cells, while KN454 was 335 
selectively active against adherent bacteria. 336 
Furthermore, the furoxans release different amounts of nitrite (KN455 > CF357 > CF1656), 337 
which has been reported to inhibit staphylococcal biofilm formation [33, 34]. Under the tested 338 
conditions, sodium nitrite alone did inhibit P. aeruginosa PAO1 biofilm formation, but showed lower 339 
activity than equimolar concentrations of KN455. Although the nitrite-effect cannot be ruled out, 340 
other mechanisms should be considered. 341 
L-cysteine prevented KN455 from inhibiting biofilm formation. It is reasonable to connect 342 
KN455 activity with its capacity to react with the thiol groups (or other nucleophilic centres) present 343 
on functional targets that are involved in cellular division and/or biofilm formation. This may also 344 
explain the activity of the 4-nitro isomer, KN454, and of the related des-NO furazan, CF389, which 345 
behave similarly in their reactions with cysteine. 346 
Cysteine has also been demonstrated to act as an antioxidant, supporting the hypothesis that 347 
furoxan and furazan can elicit oxidative stress [35]. This is in agreement with the morphological 348 
changes observed upon furoxan treatment. Indeed, filamentation is a typical stress response that 349 
occurs when cell growth continues in the absence of cell division [36]. Both highly fluorescent giant 350 
cells and other cells that showed less pronounced GFP fluorescence were observed in 351 
furoxan/furazan-treated samples. GFP expression in the first group of cells was compatible with 352 
functional transcriptomic and expression machinery. The longest bacteria showed fuzzy fluorescence, 353 
which is compatible with GFP that has been broken down following decreased protein synthesis 354 
and/or permeability stress. However, the impairment of divisome machinery and cell wall septation 355 
seems to precede a pre-death phase. The low fluorescence of filamentous cells can probably be related 356 
to decreased metabolic activity before cellular death, as the formation of multinucleate giant cells 357 
may be a pre-death phase. Both nitro-furoxans, KN455 and KN454, and furazan, CF389, seem to 358 
elicit cellular stress, which induces cellular elongation. 359 
13 
 
In conclusion, nitrofuroxan KN455 quite potently inhibits P. aeruginosa PAO1 growth and 360 
prevents PAO1 biofilm formation. This activity does not appear to be related to its capacity to release 361 
small amounts of nitric oxide, rather than nitrite. Oxidative stress and/or the impairment of divisome 362 
machinery, which is ascribable to its strong electrophilic properties, may contribute to this anti-363 
Pseudomonas activity. Additional work is necessary to investigate the intriguing differences found 364 
between furoxan KN455 and the isomer KN454, as well as to identify their target/s. 365 
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CAPTIONS 471 
 472 
 473 
Figure 1. Schematic representation of the furoxans and furazan investigated. 474 
Figure 2. Kirby-Bauer disk diffusion tests. Effect of 20 l of DMSO 0.5 %, KN455, KN454 and 475 
CF389 at a concentration of 50 mM on the growth of P. aeruginosa PAO1. 476 
Figure 3. Confocal images of P. aeruginosa PAO1 that was GFP-tagged after 24 hours of treatment 477 
with DMSO 0.5 % (A) and KN455 (B), CF389 (C) and CF1656 (D) 125 M, respectively (bar 10 478 
m). GFP expression was induced by arabinose 1 mM, one hour before confocal analyses. 479 
Figure 4. Effect of phenyl-R-substituted furoxans/furazan on the inhibition of P. aeruginosa PAO1 480 
biofilm formation. The effect was evaluated by CV staining OD595 values upon treatment for 6 hours 481 
with KN455 (A), CF357 (B), CF1656 (C), KN454 (D) and CF389 (E) at increasing concentrations, 482 
with bars representing data from at least three biological replicates and error bars representing 483 
standard deviation from the mean *, p ≤ 0.05; **, p ≤ 0.001.  484 
Figure 5.  Viable counts of the adherent (A) and planktonic (B) phases upon the inhibition of P. 485 
aeruginosa PAO1 biofilm formation exerted by furoxans/furazan 500 M. The data expressed as 486 
CFU well-1 and CFU ml-1 of survivors, respectively, are the means of at least three independent 487 
experiments ± SD * p < 0.05, ** p < 0.001 and *** p < 10-6. 488 
Figure 6. Projections and sections of CLSM images of P. aeruginosa PAO1 GFP-tagged biofilms 489 
that were subjected to furoxan/furazan and solvent treatments. Bacteria were treated for 24 hours 490 
(left) or 48 hours (right) with KN455 and  CF389  500 M or DMSO 0.5 %. The live cells that 491 
express GFP are green. 492 
Figure 7. P. aeruginosa biofilm dispersal upon treatment with furoxans at 500 M for 1h. The bars 493 
represent data from three biological replicates and error bars represent the standard deviation from 494 
the mean *, p ≤ 0.05.  495 
  496 
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Figure 8. NO and total NO2
- released by furoxans (KN455, KN454, CF357,CF1656) and furazan 497 
CF389 in the presence of L-cysteine (5:1 molar excess) at a selected time point (60 min). The results 498 
are expressed as percentage (% mol/mol) of NO or total NO2
- released with respect to the quantity of 499 
parent compound. Bars represent data from three or more replicates and error bars represent standard 500 
deviations from the mean. 501 
Figure 9. P. aeruginosa biofilm inhibition upon treatment with KN455 and Sodium Nitrite for 6 502 
hours at increasing concentrations. The error bars represent the standard deviation from the mean of 503 
three biological replicates. 504 
Figure 10. P. aeruginosa biofilm inhibition upon treatment with KN455 500 M for 6 hours in the 505 
presence and absence of L-cysteine 5 mM. The bars represent OD595 values upon Crystal Violet 506 
staining of three biological replicates, whereas error bars represent the standard deviation from the 507 
mean. 508 
 509 
